Lineagen Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 125

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7.14M

  • Investors
  • 1

Lineagen General Information

Description

Developer of a genetic testing technology designed for children with neurodevelopmental disorders. The company's technology uses chromosomal microarray (CMA) testing technology, which can detect hundreds of genetic conditions and is recommended as the first-tier test for global developmental delay according to nationally accepted guidelines, enabling physicians to personalize medical management for individuals with developmental delay and an autism spectrum disorder.

Contact Information

Formerly Known As
GenData Research, Respiris, Lineagen Research
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 2677 East Parleys Way
  • Salt Lake City, UT 84109
  • United States
+1 (801)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Diagnostic Equipment
Acquirer
Vertical(s)
Corporate Office
  • 2677 East Parleys Way
  • Salt Lake City, UT 84109
  • United States
+1 (801)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lineagen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 21-Aug-2020 $7.14M Completed Generating Revenue
15. Debt - PPP 13-Apr-2020 Completed Generating Revenue
14. Debt - General 09-Oct-2019 Completed Generating Revenue
13. Later Stage VC 23-May-2019 Completed Generating Revenue
12. Later Stage VC (Series C1) 25-Jan-2017 Completed Generating Revenue
11. Later Stage VC (Series C1) 09-Jan-2015 Completed Generating Revenue
10. Later Stage VC (Series C) 22-Nov-2013 Completed Generating Revenue
9. Later Stage VC (Series B) 24-Apr-2013 Completed Generating Revenue
8. Grant 15-Dec-2011 $622K $24.8M Completed Generating Revenue
7. Later Stage VC (Series B) 04-Jan-2011 $5M $24.8M Completed Generating Revenue
To view Lineagen’s complete valuation and funding history, request access »

Lineagen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1
Series B
Series A 1,000 $0.001000 8% $1 $1 1x $1 0%
To view Lineagen’s complete cap table history, request access »

Lineagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a genetic testing technology designed for children with neurodevelopmental disorders. The company's technol
Other Healthcare Technology Systems
Salt Lake City, UT
125 As of 2023

Sunnyvale, CA
 

Carlsbad, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lineagen Competitors (10)

One of Lineagen’s 10 competitors is Cepheid, a Formerly VC-backed company based in Sunnyvale, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cepheid Formerly VC-backed Sunnyvale, CA
ChromaCode Venture Capital-Backed Carlsbad, CA
New World Technologies Corporation New York, NY
HemoCue Corporate Backed or Acquired Ängelholm, Sweden
Ambry Genetics Formerly PE-Backed Aliso Viejo, CA
You’re viewing 5 of 10 competitors. Get the full list »

Lineagen Patents

Lineagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190247326-A1 Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof Inactive 20-Sep-2016
US-20210212960-A1 Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof Inactive 20-Sep-2016
WO-2018057484-A1 Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof Inactive 20-Sep-2016
WO-2017210456-A1 Systems, devices and methods for improved analysis and storage of genotypic and phenotypic data Inactive 01-Jun-2016
US-20170037475-A1 Genetic markers associated with asd and other childhood developmental delay disorders Inactive 09-Apr-2014 C12Q1/6883
To view Lineagen’s complete patent history, request access »

Lineagen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lineagen Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Archipel Capital Venture Capital Minority
Hatteras Investment Partners Fund of Funds Minority
HealthQuest Capital Growth/Expansion Minority
Kickstart (US) Venture Capital Minority
Kinect Capital Accelerator/Incubator
You’re viewing 5 of 17 investors. Get the full list »

Lineagen FAQs

  • When was Lineagen founded?

    Lineagen was founded in 2006.

  • Where is Lineagen headquartered?

    Lineagen is headquartered in Salt Lake City, UT.

  • What is the size of Lineagen?

    Lineagen has 125 total employees.

  • What industry is Lineagen in?

    Lineagen’s primary industry is Other Healthcare Technology Systems.

  • Is Lineagen a private or public company?

    Lineagen is a Private company.

  • What is the current valuation of Lineagen?

    The current valuation of Lineagen is .

  • What is Lineagen’s current revenue?

    The current revenue for Lineagen is .

  • How much funding has Lineagen raised over time?

    Lineagen has raised $53.4M.

  • Who are Lineagen’s investors?

    Archipel Capital, Hatteras Investment Partners, HealthQuest Capital, Kickstart (US), and Kinect Capital are 5 of 17 investors who have invested in Lineagen.

  • Who are Lineagen’s competitors?

    Cepheid, ChromaCode, New World Technologies, HemoCue, and Ambry Genetics are some of the 10 competitors of Lineagen.

  • When was Lineagen acquired?

    Lineagen was acquired on 21-Aug-2020.

  • Who acquired Lineagen?

    Lineagen was acquired by Bionano Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process